Sigma Pharmaceutical : Daily share buy-back notice - Appendix 3E
January 23, 2017 at 06:00 pm EST
Share
Appendix 3E Daily share buy-back notice
Appendix 3E
Daily share buy-back notice (except minimum holding buy-back and
selective buy-back)
Information and documents given to ASX become ASX's property and may be made public.
Rule 3.8A
Name of entity
ABN/ARSN
Sigma Pharmaceuticals Limited
15 088 417 403
We (the entity) give ASX the following information.
Information about buy-back
1
Type of buy-back
On-market buy-back
2
Date Appendix 3C was given to ASX
13 September 2012
(Associated Appendix 3D dated 11 November 2016)
Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day
Before previous day
Previous day
3
Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received
114,300,105
836,804
4
Total consideration paid or payable for the shares/units
$84,384,728
$991,613
Appendix 3E
Daily share buy-back notice
Before previous day
Previous day
5
If buy-back is an on-market buy- back
Highest price paid:
$1.2300
Lowest price paid:
$0.5600
Highest price paid:
$1.2000
Lowest price paid:
$1.1675
Highest price allowed under rule 7.33:
$1.2920
How many shares/units may still be bought back?
6
If the company/trust has disclosed an intention to buy back a maximum number of shares/units - the remaining number of shares/units to be bought back
3,493,443
Compliance statement
The company is in compliance with all Corporations Act requirements relevant to this buy-back.
There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.
or, for trusts only:
The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.
Sign here: Date: 24 January 2017
(Director/Company secretary)
Print name: Sam Lawson
Sigma Pharmaceuticals Limited published this content on 24 January 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 23 January 2017 23:00:06 UTC.
Original documenthttp://phx.corporate-ir.net/external.file?t=2&item=o8hHt16027g9XhJTr8+weNRYaV9bFc2rMd0Q/AXw4zs0sMqTLP4ZGLiDGtv+KiWaRkP4b62l4G9D3utAhWJhbVCyPmf3HVAIIm2OHhJIeP9DZTvKs/C6bPRYSRrHjhX4QC9FDr2vPPCN1FqLU5qxaQ==&cb=636208086756515178
Public permalinkhttp://www.publicnow.com/view/6BA3A42BB164EFFFC74903DBEE6115A411AB0CE6
Sigma Healthcare Limited is an Australia-based company. The principal activities of the Company are the wholesale distribution of pharmaceutical goods and medical consumables to community pharmacies. Its brands include Amcal, Guardian, and Discount Drug Stores. The Company provides a range of solutions, including dispensary services, data and technology, health services, team training, private and exclusive label, sigma rewards, sigma financial services, and supply network and logistics. Its dispensary services provide pharma program, sigma ethical partnership program, and dose administration aid program. Its data and technology provide e-prescription support, health opportunities and sigma performance dashboard tool. Its health services include pharmacy practice support, LEAPP dispensary program, PSS sleep apnoea program and sigma dose administration aid program. Its team training involves sigma online training platform, retail pharmacy programs, and quality care resource hub.
SIGMA HEALTHCARE LTD 
